PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression
Open accessThe DOI matches its Crossref record; 84 of the 87 references it cites were found in a registry or an index.
Abstract
Targeted therapy with small molecules directed at essential survival pathways in leukemia represents a major advance, including the phosphatidylinositol-3'-kinase (PI3K) p110δ inhibitor idelalisib. Here, we found that genetic inactivation of p110δ (p110δD910A/D910A) in the Eμ-TCL1 murine chronic lymphocytic leukemia (CLL) model impaired B cell receptor signaling and B cell migration, and significantly delayed leukemia pathogenesis. Regardless of TCL1 expression, p110δ inactivation led to rectal prolapse in mice resembling autoimmune colitis in patients receiving idelalisib. Moreover, we showed that p110δ inactivation in the microenvironment protected against CLL and acute myeloid leukemia. After receiving higher numbers of TCL1 leukemia cells, half of p110δD910A/D910A mice spontaneously recovered from high disease burden and resisted leukemia rechallenge. Despite disease resistance, p110δD910A/D910A mice exhibited compromised CD4+ and CD8+ T cell response, and depletion of CD4+ or CD8+ T cells restored leukemia. Interestingly, p110δD910A/D910A mice showed significantly impaired Treg expansion that associated with disease clearance. Reconstitution of p110δD910A/D910A mice with p110δWT/WT Tregs reversed leukemia resistance. Our findings suggest that p110δ inhibitors may have direct antileukemic and indirect immune-activating effects, further supporting that p110δ blockade may have a broader immune-modulatory role in types of leukemia that are not sensitive to p110δ inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mice bearing an inactivating mutation in Pik3cd exhibit superior resistance to chronic lymphocytic leukemia (CLL) in the context of impaired TREG cell expansion (Dong et al., 2019; Hanna et al., 2019)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Dong et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
The microbiota in adaptive immune homeostasis and disease
Honda, K., & Littman, D. R. (2016) · Nature · doi:10.1038/nature18848 · Cited by 1,846
Dysbiosis and the immune system
Levy, M., Kolodziejczyk, A. A., Thaiss, C. A., & Elinav, E. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.7 · Cited by 1,769
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.015 · Cited by 1,392
‘Acute myeloid leukemia: a comprehensive review and 2016 update’
De Kouchkovsky, I., & Abdul-Hay, M. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.50 · Cited by 1,317
Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice
Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A., Waterfield, M. D., et al. (2002) · Science · doi:10.1126/science.1073560 · Cited by 946
Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Self-citationAnalysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation
Fabbri, G., Rasi, S., Rossi, D., Trifonov, V., Khiabanian, H., Ma, J., Grunn, A., Fangazio, M., Capello, D., Monti, S., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110921 · Cited by 610
Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape
Mohme, M., Riethdorf, S., & Pantel, K. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.144 · Cited by 602
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Self-citationPI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 476
Self-citationYan, Y., Huang, L., Liu, Y., Yi, M., Chu, Q., Jiao, D., & Wu, K. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01322-3 · Cited by 212
“Since the participation of PI3K-p110δ in promoting Treg migration has been extensively studied, PI3K p110δ antagonists, such as idelalisib, have been broadly applied as immune modulators to treat hematologic malignancies [113].”
BackgroundImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
Roessner, P. M., & Seiffert, M. (2020) · Leukemia · doi:10.1038/s41375-020-0873-2 · Cited by 144
“inhibitors which contributes to such adverse events [32, 96, 97].”
BackgroundIntermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
Eschweiler, S., Ramírez-Suástegui, C., Li, Y., King, E., Chudley, L., Thomas, J., Wood, O., von Witzleben, A., Jeffrey, D., McCann, K., et al. (2022) · Nature · doi:10.1038/s41586-022-04685-2 · Cited by 99
Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity
Sun, P., & Meng, L. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00500-8 · Cited by 81
Murali, I., Kasar, S. N., Naeem, A. S., Tyekucheva, S., Khalsa, J. K., Thrash, E. M., Itchaki, G., Livitz, D. G., Leshchiner, I., Dong, S., et al. (2021) · Blood · doi:10.1182/blood.2020006765 · Cited by 73
Self-citationAldinucci, D., Borghese, C., & Casagrande, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102416 · Cited by 63
“Idelalisib is the first PI3K-δ inhibitor to be approved for follicular lymphoma [163] and chronic lymphocytic leukemia [164].”
BackgroundTargeting the metabolism of tumor-infiltrating regulatory T cells
Wang, Y., Huang, T., Gu, J., & Lu, L. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.06.001 · Cited by 62
Class IA PI3Ks regulate subcellular and functional dynamics of IDO1
Iacono, A., Pompa, A., Marchis, F. D., Panfili, E., Greco, F. A., Coletti, A., Orabona, C., Volpi, C., Belladonna, M. L., Mondanelli, G., et al. (2020) · EMBO Reports · doi:10.15252/embr.201949756 · Cited by 50
“In neoplastic conditions, activation of PI3K p110 d can indeed induce proliferation and survival of tumor cells as well as potentiation of immunoregulatory mechanisms in both tumor and immune cells, thus dampening anti-tumor immunity (Dong et al , 2019).”
Shin, N., Stubbs, M. C., Koblish, H. K., Yue, E. W., Soloviev, M. V., Douty, B. D., Wang, K. H., Wang, Q., Gao, M., Feldman, P., et al. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.265538 · Cited by 47
“Idelalisibmay causehepatotoxicity by immuneactivation, since peripheral blood regulatory T cells (Tregs) were seen in patients experiencing hepatotoxicity while receiving idelalisib treatment (Lampson et al., 2016).”
BackgroundInfluentialTargeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting
Qiang, M., Chen, Z., Liu, H., Dong, J., Gong, K., Zhang, X., Huo, P., Zhu, J., Shao, Y., Ma, J., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1516583 · Cited by 66
Kater, A. P., Slinger, E., Cretenet, G., Martens, A. W. J., Balasubramanian, S., Leverson, J. D., & Eldering, E. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004861 · Cited by 44
Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies
Maharaj, K. K., Uriepero, A., Sahakian, E., & Pinilla-Ibarz, J. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943354 · Cited by 46
Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
Lauder, S. N., Smart, K., Kersemans, V., Allen, P. D., Scott, J., Pires, A., Milutinovic, S., Somerville, M. S., Smart, S., Kinchesh, P., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000693 · Cited by 44
Maharaj, K. K., Powers, J. J., Mediavilla-Varela, M., Achille, A. N., Gamal, W. M., Quayle, S. N., Jones, S. S., Sahakian, E., & Pinilla-Ibarz, J. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.590072 · Cited by 36
PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
Tarantelli, C., Argnani, L., Zinzani, P. L., & Bertoni, F. (2021) · Cancers · doi:10.3390/cancers13215535 · Cited by 40
Serrat, N., Guerrero-Hernández, M., Matas-Céspedes, A., Yahiaoui, A., Valero, J. G., Nadeu, F., Clot, G., Di Re, M., Corbera-Bellalta, M., Magnano, L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001584 · Cited by 32
“Moreover, recent findings indicate that PI3Kd inhibitors could also be used to target the immune system by dampening Treg activity and facilitating host–antitumor responses.(16,17)”
BackgroundPhosphatidylinositol 3 Kinase δ Inhibitors
Brown, J. R. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000414 · Cited by 33
Self-citationPI3K Inhibitors in Hematology: When One Door Closes…
Skånland, S. S., Okkenhaug, K., & Davids, M. S. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0967 · Cited by 31
Wang, Z., Zhou, H. J., Xu, J., Wang, J., & Niu, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1070660 · Cited by 34
Relevance function of microRNA-708 in the pathogenesis of cancer
Sun, S., Hu, S., Shang, Y.-P., Li, L., Zhou, H., Chen, J.-S., Yang, J., Li, J., Huang, Q., Shen, C., et al. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109390 · Cited by 27
Stein, A. F. V., Rebollido-Rios, R., Lukas, A., Koch, M., von Lom, A., Reinartz, S., Bachurski, D., Rose, F., Bożek, K., Abdallah, A. T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36824-2 · Cited by 28
Control of T lymphocyte fate decisions by PI3K signaling
Murter, B., & Kane, L. (2020) · F1000Research · doi:10.12688/f1000research.26928.1 · Cited by 26
Aydin, E., Faehling, S., Saleh, M., Cid, L. L., Seiffert, M., & Roessner, P. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.595818 · Cited by 27
“And a reduced proliferation of CD8 T-cells has been observed after PI3Kd inhibitor treatment in vivo in the preclinical TCL1 AT model of CLL (134) as well as in another model, in which OVA-expressing TCL1 leukemic cells were transplanted into PI3Kd mice (147).”
BackgroundMethodResultInfluentialHofland, T., de Weerdt, I., ter Burg, H., de Boer, R., Tannheimer, S., Tonino, S. H., Kater, A. P., & Eldering, E. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900321 · Cited by 21
Pretto, S., Yu, Q., Bourdely, P., Cafarello, S. T., Acker, H. H. V., Verelst, J., Richiardone, E., Vanheer, L., Roshanzadeh, A., Schneppenheim, F., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01233-w · Cited by 26
Akhiani, A. A., Hallner, A., Kiffin, R., Aydin, E., Werlenius, O., Aurelius, J., Martner, A., Thorén, F. B., & Hellstrand, K. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0055 · Cited by 20
Yano, M., Byrd, J. C., & Muthusamy, N. (2022) · Cancers · doi:10.3390/cancers14235787 · Cited by 19
Self-citationKohlhas, V., Hallek, M. J., & Nguyen, P. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002584 · Cited by 15
Öztürk, S., Roessner, P. M., Jassowicz, L., Yazdanparast, H., Kalter, V., Lichter, P., Hanna, B. S., & Seiffert, M. (2019) · Leukemia · doi:10.1038/s41375-018-0332-5 · Cited by 15
Koch, M., Reinartz, S., Saggau, J., Knittel, G., Rosen, N., Fedorchenko, O., Thelen, L., Barthel, R., Reinart, N., Seeger‐Nukpezah, T., et al. (2020) · Cancers · doi:10.3390/cancers12071980 · Cited by 15
Ding, X., Xiang, W., Yi, R., Huang, X., Lin, Q., & He, X. (2021) · Immunology · doi:10.1111/imm.13379 · Cited by 13
Gadi, D., Griffith, A. M., Wang, Z., Tyekucheva, S., Rai, V., Fernandes, S. M., Machado, J., Munugalavadla, V., Lederer, J. A., & Brown, J. R. (2022) · British Journal of Haematology · doi:10.1111/bjh.18053 · Cited by 17
Self-citationTao, Q., Chen, Y., Liang, X. H., Hu, Y., Li, J., Fang, F., Wang, H., Meng, C., Liang, J., Ma, X., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112143 · Cited by 15
Immunotherapy for hematological malignancies
Dong, S., & Ghobrial, I. M. (2019) · JoLS Journal of Life Sciences · doi:10.36069/jols/20190605 · Cited by 13
“Nivolumab and pembrolizumanb are two anti-PD1 Ab at the most advanced stage of clinical trials in hematological malignancies for HL, non-Hodgkin’s Lymphoma (nHL), CLL and MM. FDA had approved the use of nivolumab and pembrolizumab in relapsed/refractory HL in 2016 and 2017 respectively (Table 2) The “success” of PD-1…”
BackgroundSelf-citationMachado, A. K. D. C., Machado, C. B., Pessoa, F. M. C. D. P., Barreto, I. V., Gadelha, R. B., Oliveira, D. D. S., Ribeiro, R. M., Lopes, G. S., de Moraes, M. O., de Moraes, M. E. A., et al. (2024) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10279 · Cited by 16
Lessons learned from the Eµ-TCL1 mouse model of CLL
Floerchinger, A., & Seiffert, M. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.05.002 · Cited by 11
Chen, S., Barrientos, J. C., Ferrer, G., King-Richards, M., Chen, Y.-J., Ravichandran, P., Ibrahim, M., Kieso, Y., Waters, S., Kutok, J. L., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2386 · Cited by 13
Lambrou, G. Ι., Adamaki, M., Hatziagapiou, K., & Vlahopoulos, S. (2020) · Current Drug Research Reviews · doi:10.2174/2589977512666200220122650 · Cited by 6
PI3K Targeting in Non-solid Cancer
Kim, H. N., Ogana, H. A. N., Sanchez, V. E., Nichols, C. M., & Kim, Y. (2022) · Current topics in microbiology and immunology · doi:10.1007/978-3-031-06566-8_17 · Cited by 6
Phase Ib study of the oral PI3Kδ inhibitor linperlisib in patients with advanced solid tumors
Li, J., Xue, J., Liu, T., Feng, Y., Xu, N., Huang, J., Yin, Y., Zhang, J., Mou, H., Shentu, J., et al. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02657-2 · Cited by 6
PI3Kγ in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target
Luo, Q., Fortune, A., & Lane, A. A. (2025) · Blood · doi:10.1182/blood.2024027376 · Cited by 3
Zhao, K., Li, X., Zhu, Q., Zhu, M., Huang, J., & Zhao, T. S. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1527713 · Cited by 4
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors
Gadi, D., Martindale, S. P., Chiu, P. Y., Khalsa, J. K., Chen, P.-H., Fernandes, S. M., Wang, Z., Tyekucheva, S., Machado, J., Fisher, D. C., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00788-9 · Cited by 3
“A mouse with a kinase dead PI3Kδ develops colitis, similar to patients treated with PI3Kδ inhibitors, but also resists the development of leukemia and can acquire protective anti-cancer immunity [8].”
BackgroundSelf-citationPI3Kδ Mediates Fibrosis by Patient-Derived Vitreous
Liu, D., Yan, B., Yin, Y., Chen, F., Guo, C., Li, Q., Liu, J., Li, P., Wu, W., & Luo, J. (2024) · Laboratory Investigation · doi:10.1016/j.labinv.2024.102026 · Cited by 3
Akhiani, A. A., Hallner, A., Kiffin, R., Aydin, E., Werlenius, O., Aurelius, J., Martner, A., Thorén, F. B., & Hellstrand, K. (2023) · doi:10.1158/2326-6066.c.6550396
Akhiani, A. A., Hallner, A., Kiffin, R., Aydin, E., Werlenius, O., Aurelius, J., Martner, A., Thorén, F. B., & Hellstrand, K. (2023) · doi:10.1158/2326-6066.c.6550396.v1
Pharmacologic Differentiation of Drugs Targeting the PI 3K‐ AKT ‐m TOR Signaling Pathway
Ahn, I. E., Brown, A. J. R., & Davids, M. S. (2023) · Wiley eBooks · doi:10.1002/9781119819950.ch6
Chen, S., Barrientos, J. C., Ferrer, G., King-Richards, M., Chen, Y.-J., Ravichandran, P., Ibrahim, M., Kieso, Y., Waters, S., Kutok, J. L., et al. (2023) · doi:10.1158/1078-0432.c.6605170.v2
Wierz, M. (2020) · theses.fr (ABES) · doi:10.70675/80454a47z3b6bz4b8bza0c3z684d69f087b3 · Cited by 1
Metadata
- Authors
- Dong, S., Harrington, B. K., Hu, E. Y., Greene, J. T., Lehman, A. M., Tran, M., Wasmuth, R. L., Long, M., Muthusamy, N., Brown, J. R., Johnson, A. J., & Byrd, J. C.
- Affiliations
- The Ohio State University (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Johnson, Amy J.
- Byrd, John C.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-11-19
- Volume
- 129
- Issue
- 1
- Pages
- 122-136
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6307940
- OpenAlex
- W2900480369
- Cited by
- 52
- References
- 87
- Citations by year
- 2025: 4 · 2024: 5 · 2023: 10 · 2022: 6 · 2021: 6 · 2020: 15 · 2019: 6
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA159296)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- PI3K p110δ, chronic lymphocytic leukemia, idelalisib, T cell suppression, regulatory T cells, B cell receptor signaling, B cell migration, acute myeloid leukemia, rectal prolapse, autoimmune colitis, tumor microenvironment, TCL1, leukemia resistance, immunomodulation
- MeSH terms
- Animals, Enzyme Activation, Immune Tolerance, Leukemia, Lymphoid, Mice, Transgenic, Neoplasms, Experimental, CD8-Positive T-Lymphocytes, Amino Acid Substitution, Mutation, Missense, T-Lymphocytes, Regulatory, Mice, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.